Pharmaceuticals
Bovine Vaccines Market

Bovine Vaccines Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

Bovine Vaccines Market By Vaccine Type (Live Attenuated, Inactivated, Toxoid), by Disease Type (FMD, Brucellosis, Bovine Respiratory Disease), End-user (Cattle Farms, Veterinary Clinics, and Government Agencies), and Regional Analysis for 2025 - 2032

ID: PMRREP35515

July 2025

198 Pages

Author : Abhijeet Surwase

Healthcare

Bovine Vaccines Market Size and Trends Analysis

The global bovine vaccines market size is likely to be valued at US$ 3.99 Bn in 2025 and is expected to reach US$ 5.94 Bn by 2032, growing at a CAGR of 4.9% in the forecast period from 2025 to 2032. Rising demand for livestock health management and the increasing prevalence of infectious cattle diseases such as foot-and-mouth disease (FMD), bovine viral diarrhea (BVD), and brucellosis attract growth.

As the global meat and dairy industries expand, it drives the emphasis on preventive veterinary care to ensure animal productivity and food safety. Technological advancements in livestock vaccination solutions, including recombinant and DNA-based vaccines, are reshaping the market landscape, offering more effective and targeted immunization. The market is also benefiting from increasing investments by key players to develop cattle disease prevention products that address region-specific challenges and evolving pathogens.

global bovine vaccines market size 2025–2032

Key Industry Highlights:

Live attenuated vaccines continue to lead the market, accounting for a 36.5% share, due to their long-lasting immunity and cost-effective application in large-scale immunization programs.
North America remains the dominant regional market, with a share of 34% supported by advanced veterinary infrastructure and government-backed disease control initiatives.
The recent launch of specialized vaccines such as Merck’s cryptosporidiosis vaccine and Ceva’s BLUEVAC-3 for bluetongue marks a significant shift toward niche disease targeting and regulatory expansion.
Thermostable vaccine development is gaining momentum, particularly for regions with weak cold-chain systems, improving vaccine accessibility in rural and tropical zones.
Growing emphasis on antibiotic-free animal health and rising consumer awareness around food safety are fueling the demand for preventive veterinary care over therapeutic treatment.
Strategic collaborations between governments, global health organizations, and vaccine manufacturers are reshaping livestock disease management, especially in Asia and Africa, where mass vaccination campaigns are scaling rapidly.

Market Attribute	Key Insights
Bovine Vaccines Market Size (2025E)	US$ 3.99 Bn
Market Value Forecast (2032F)	US$ 5.94 Bn
Projected Growth (CAGR 2025 to 2032)	4.9%
Historical Market Growth (CAGR 2019 to 2024)	4.1%

Market Dynamics

Driver- Rising Regulatory Mandates on Curbing Antimicrobial Resistance Pushing Farmers to Shift from Routine Antibiotic Use to Precision Cattle Immunization Strategies

The rising regulatory mandates on curbing antimicrobial resistance are pushing farmers and regulators to shift from routine antibiotic use to precision cattle immunization strategies. This trend is most pronounced in North America, Europe, and Asia, where guidelines now favor vaccines over prophylactic antibiotics to address public health concerns. The clear return-on-investment from disease prevention vaccines is seen in reduced herd mortality, improved feed conversion, and lower cull rates. This drives both large-scale ranches and smallholders to adopt bovine vaccines proactively.

Innovations in thermostable vaccine formulations are alleviating cold-chain challenges in tropical and remote farming regions, improving access and reducing spoilage. Simultaneously, multivalent cattle vaccines that protect against multiple pathogens in a single dose are gaining traction by simplifying labor and lowering logistics costs. Moreover, DNA-based cattle vaccines are emerging as targeted, low-reactogenic solutions, strengthening herd immunity without compromising safety.

Restraint- Rigorous Recombinant Bovine Vaccine Manufacturing Demands Specialized Facilities and Highly Skilled Personnel, Raising Entry Barriers and Keeping Prices High

The steep investment in autogenous cattle vaccine development, including antigen customization and safety validation, escalates the cost per dose, far beyond standardized vaccines. Rigorous recombinant bovine vaccine manufacturing demands specialized facilities and highly skilled personnel, raising entry barriers and keeping prices high, particularly for emerging-market farmers. These production constraints hinder widespread adoption of advanced vaccines across price-sensitive rural regions, where cost remains a critical deterrent.

Maintaining thermostable vaccine integrity is challenging as cold-chain interruptions in remote regions often result in up to 30-40% dose spoilage, reducing farmer confidence and increasing per-dose cost. Meanwhile, heterogeneous regulatory approvals across countries inflate time-to-market for novel bovine vaccines, forcing manufacturers to navigate overlapping safety and licensing frameworks, delaying access, and increasing costs. These combined challenges slow the adoption of innovative formulations such as multivalent or DNA-based vaccines.

Opportunity- Innovation in IoT-powered Cold-chain Modules, Providing Affordable, Low-cost Vaccine Storage Solutions

Manufacturers are capitalizing on the growing demand for autogenous cattle vaccines, which are custom-made using herd-specific strains to combat localized outbreaks such as lumpy skin disease. This tailor-made approach enhances efficacy in high-risk areas such as India and Southeast Asia, where farmers are increasingly seeking targeted biosecurity solutions. The evolution of recombinant and DNA-based bovine vaccines offers precise pathogen targeting with high safety profiles, accelerating uptake on commercial farms investing in cutting-edge immunization technologies.

Innovation in IoT-powered cold-chain modules such as ALIVE provides affordable, low-cost vaccine storage solutions, minimizing dose loss in remote farming regions and offering real-time temperature monitoring, opening expansion in underserved areas across Africa and Asia Pacific. Coupled with digital farm platforms, which integrate vaccine tracking, health monitoring, and scheduling, this technology empowers farmers with transparent livestock vaccination records, fueling adoption of advanced vaccines via digital trust-building.

Get Your CustomizationGet Your Customization

Category-Wise Analysis

Vaccine Type Insights

Live attenuated vaccines dominate with approximately 36.5% market share, driven by their ability to induce long-lasting immunity with just one or two doses and strong protection against diseases such as FMD, brucellosis, and BRD. Inactivated (Killed) Vaccines are favored for their safety profile and regulatory acceptance, and they are the fastest-growing segment due to improved efficacy and increased awareness. Subunit, Recombinant, and Toxoid Vaccines represent the evolving edge of bovine immunology. These vaccines utilize purified antigens or synthetic proteins to deliver targeted immune responses with minimal side effects.

Disease Type Insights

BRD (Bovine Respiratory Disease Complex) leads disease-targeted vaccines with a 32% share, driven by high morbidity and the need for multivalent respiratory protection. The segment is also the fastest-growing, driven by the high economic burden per case and the expanding usage in feedlot operations globally. Mastitis, a leading cause of economic loss in the dairy sector, has become a central driver for vaccine investment, especially in regions where milk yield and quality are crucial market differentiators. Foot-and-Mouth Disease (FMD) remains a high-priority disease in many low- and middle-income countries, prompting aggressive national and regional vaccination campaigns.

global bovine vaccines market outlook by vaccine 2025–2032

Regional Insights

North America Bovine Vaccines Market Trends

North America leads the global bovine vaccines market, capturing roughly 34% of the share thanks to its advanced veterinary healthcare system and strong government support. The region benefits from a highly structured veterinary healthcare system, strong regulatory oversight, and substantial government funding for livestock disease control.

In the U.S., the USDA and APHIS (Animal and Plant Health Inspection Service) have collaborated with private vaccine developers to ensure high standards for immunization programs. Bovine respiratory diseases and mastitis are the most targeted indications with widespread use of recombinant and DNA-based cattle vaccines among large-scale dairy and beef producers. Cold-chain integrity, traceability, and data-driven livestock health tracking are also well established in this region, enabling the effective delivery and monitoring of complex vaccination schedules. The rising emphasis on antibiotic-free animal husbandry further boosts demand for vaccines as a primary disease prevention tool.

Europe Bovine Vaccines Market Trends

Europe holds approximately 27% of the market. Its growth is driven by stringent animal welfare protocols and structured disease control programs. Countries such as Germany, France, the UK, and the Netherlands have long-standing vaccination mandates for diseases such as bovine viral diarrhea (BVD), bluetongue, and foot-and-mouth disease (FMD).

The EU's focus on food safety and animal traceability promotes the use of DIVA-compatible subunit and recombinant vaccines, especially in export-oriented cattle operations. Regional governments also invest in large-scale immunization campaigns in partnership with veterinary agencies. Europe is actively involved in the research and development of next-generation cattle vaccines, including thermostable and mRNA-based platforms, through collaborations between biotech firms and academic institutions. The continent also sees a growing trend toward needle-free cattle vaccine delivery systems and improved veterinary diagnostics to enhance disease surveillance.

Asia Pacific Bovine Vaccines Market Trends

Asia Pacific is experiencing the fastest growth, with a current market share of 22% and a projected CAGR of 7.8% during the forecast period. Rise in cattle population, growing awareness among livestock farmers, and proactive government-led immunization initiatives are some major growth factors. India and China lead the region, accounting for a significant portion of global bovine headcount.

In India, national programs such as the National Animal Disease Control Programme (NADCP) aim to eradicate FMD and brucellosis through sustained mass vaccination drives. Meanwhile, China continues to strengthen its animal health system to meet rising protein demands and biosecurity standards. Southeast Asian countries such as Indonesia, Vietnam, and Thailand are also expanding cattle vaccination coverage, particularly for zoonotic diseases. However, infrastructural gaps, cold-chain limitations, and lack of trained veterinary staff remain challenges. Despite this, the demand for thermostable, multivalent, and low-cost cattle vaccines is surging, opening opportunities for both local manufacturers and multinational players.

global bovine vaccines market outlook by region 2025-2032

Request Free sampleRequest Free sample

Competitive Analysis

The global bovine vaccines market is highly competitive, led by established pharmaceutical giants and supported by emerging regional players. Companies such as Zoetis Inc., Merck Animal Health, and Boehringer Ingelheim Animal Health dominate due to their extensive product portfolios, global distribution networks, and investments in next-generation vaccine technologies. These companies also focus on value-added services such as vaccine scheduling, traceability, and diagnostics to maintain long-term relationships with large cattle farms and veterinary networks. Reflecting a widespread transformation, the market is moving toward thermostable formulations, autogenous vaccines, and digital integration, reflecting the industry’s response to region-specific challenges and demand for precise, scalable, and affordable cattle immunization solutions.

Key Industry Developments:

In January 2024, Kyoto Biken Laboratories, Inc. expanded its presence in the Middle East after receiving regulatory approval from UAE authorities for a suite of bovine vaccines, including Cattlewin-5k, Calfwin 6 Combo Live, and Ovine Ephemeral Fever Vaccine.
In August 2024, Merck also secured authorization from the U.K. Veterinary Medicines Directorate (VMD) for the first-ever vaccine protecting cattle against cryptosporidiosis, a gastrointestinal disease with high morbidity in young calves, filling a major unmet need in calf health.

Companies Covered in Bovine Vaccines Market

Zoetis Inc.
Merck Animal Health (MSD)
Boehringer Ingelheim Animal Health
Ceva Santé Animale
Elanco Animal Health
Indian Immunologicals Ltd.
Hester Biosciences Ltd.
Bayer Animal Health
Kyoto Biken Laboratories, Inc.
Virbac
Phibro Animal Health Corporation
Biogenesis Bagó
Brilliant Bio Pharma Pvt. Ltd.
Hipra
Avimex Animal Health
China Animal Husbandry Industry Co., Ltd. (CAHIC)

Frequently Asked Questions

The global bovine vaccines market is expected to be valued at approximately US$ 3.99 Bn in 2025, driven by rising demand for preventive livestock care and large-scale immunization programs.

By 2032, the bovine vaccines market is projected to reach around US$ 5.94, reflecting growing adoption of advanced vaccines and increased government-led disease eradication efforts.

Key trends include the rise of thermostable and recombinant vaccines, mRNA and subunit-based innovations, increasing use of DIVA-compliant vaccines, and integration of digital herd health platforms to track vaccine efficacy and livestock immunity.

Among all segments, live attenuated vaccines dominate by vaccine type, while bovine respiratory disease (BRD) leads by disease type due to its high prevalence and economic impact on the global cattle industry.

The bovine vaccines market is expected to grow at a CAGR of 4.9% from 2025 to 2032, driven by increasing disease outbreaks, expanding commercial cattle farming, and enhanced veterinary infrastructure in emerging economies.

Major players with strong product portfolios and global reach include Zoetis Inc., Merck Animal Health, Boehringer Ingelheim Animal Health, Ceva Santé Animale, Indian Immunologicals Ltd.

Top-Down Market Sizing	Bottom-Up Market Sizing
Universe Definition: Total global/regional market identification	Unit Economics: Average transaction values, purchase frequencies, customer lifecycle
Segmentation Filters: Geographic, demographic, and behavioral constraints	Customer Segmentation: Detailed buyer persona development and sizing
Market Share Analysis: Competitive landscape assessment and share allocation	Penetration Analysis: Market penetration rates by segment and geography
Growth Rate Application: Historical trends and forward-looking growth assumptions	Scaling Methodology: Extrapolation techniques with confidence intervals

Interested in this report?

Request customization, ask for expert consulting, access a sample report, or simply express your interest—our team will assist you with the right insights and solutions.

Request Custom VersionRequest Custom Version

Clients

Media Citation

Get In Touch

Loading page data

Please wait a moment

Executive Summary
1. Global Bovine Vaccines Market Snapshot, 2025 and 2032
2. Market Opportunity Assessment, 2025 - 2032, US$ Bn
3. Key Market Trends
4. Future Market Projections
5. Premium Market Insights
6. Industry Developments and Key Market Events
7. PMR Analysis and Recommendations
Market Overview
1. Market Scope and Definition
2. Market Dynamics
  1. Drivers
  2. Restraints
  3. Opportunity
  4. Key Trends
3. Macro-economic Factors
  1. Global Sectoral Outlook
  2. Global GDP Growth Outlook
4. COVID-19 Impact Analysis
5. Forecast Factors - Relevance and Impact
Value Added Insights
1. Tool Adoption Analysis
2. Regulatory Landscape
3. Value Chain Analysis
4. PESTLE Analysis
5. Porter’s Five Force Analysis
Price Analysis, 2024A
1. Key Highlights
2. Key Factors Impacting Deployment Costs
3. Pricing Analysis, By Component Type
Global Bovine Vaccines Market Outlook
1. Key Highlights
  1. Market Volume (Units) Projections
  2. Market Size (US$ Bn) and Y-o-Y Growth
  3. Absolute $ Opportunity
2. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast
  1. Historical Market Size (US$ Bn) Analysis, 2019-2024
  2. Market Size (US$ Bn) Analysis and Forecast, 2025 - 2032
3. Global Bovine Vaccines Market Outlook: Vaccine Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Vaccine Type, 2019 - 2024
  3. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Vaccine Type, 2025 - 2032
    1. Live Attenuated
    2. Inactivated
    3. Toxoid
    4. Subunit
    5. DNA vaccines
  4. Market Attractiveness Analysis: Vaccine Type
4. Global Bovine Vaccines Market Outlook: Disease Type
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By Disease Type, 2019 - 2024
  3. Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 - 2032
    1. FMD
    2. Brucellosis
    3. Bovine respiratory disease
    4. Others
  4. Market Attractiveness Analysis: Disease Type
5. Global Bovine Vaccines Market Outlook: End-User
  1. Introduction / Key Findings
  2. Historical Market Size (US$ Bn) Analysis, By End-User, 2019 - 2024
  3. Market Size (US$ Bn) Analysis and Forecast, By End-User, 2025 - 2032
    1. Cattle Farms
    2. Veterinary Clinics
    3. Government Agencies
  4. Market Attractiveness Analysis: End-User
Global Bovine Vaccines Market Outlook: Region
1. Key Highlights
2. Historical Market Size (US$ Bn) and Volume (Units) Analysis, By Region, 2019 - 2024
3. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Region, 2025 - 2032
  1. North America
  2. Europe
  3. East Asia
  4. South Asia and Oceania
  5. Latin America
  6. Middle East & Africa
4. Market Attractiveness Analysis: Region
North America Bovine Vaccines Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Vaccine Type
  3. By Disease Type
  4. By End-User
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. U.S.
  2. Canada
4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Vaccine Type, 2025 - 2032
  1. Live Attenuated
  2. Inactivated
  3. Toxoid
  4. Subunit
  5. DNA vaccines
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 - 2032
  1. FMD
  2. Brucellosis
  3. Bovine respiratory disease
  4. Others
6. Market Size (US$ Bn) Analysis and Forecast, By End-User, 2025 - 2032
  1. Cattle Farms
  2. Veterinary Clinics
  3. Government Agencies
7. Market Attractiveness Analysis
Europe Bovine Vaccines Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Vaccine Type
  3. By Disease Type
  4. By End-User
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. Germany
  2. France
  3. U.K.
  4. Italy
  5. Spain
  6. Russia
  7. Türkiye
  8. Rest of Europe
4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Vaccine Type, 2025 - 2032
  1. Live Attenuated
  2. Inactivated
  3. Toxoid
  4. Subunit
  5. DNA vaccines
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 - 2032
  1. FMD
  2. Brucellosis
  3. Bovine respiratory disease
  4. Others
6. Market Size (US$ Bn) Analysis and Forecast, By End-User, 2025 - 2032
  1. Cattle Farms
  2. Veterinary Clinics
  3. Government Agencies
7. Market Attractiveness Analysis
East Asia Bovine Vaccines Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Vaccine Type
  3. By Disease Type
  4. By End-User
  5. By End User
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. China
  2. Japan
  3. South Korea
4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Vaccine Type, 2025 - 2032
  1. Live Attenuated
  2. Inactivated
  3. Toxoid
  4. Subunit
  5. DNA vaccines
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 - 2032
  1. FMD
  2. Brucellosis
  3. Bovine respiratory disease
  4. Others
6. Market Size (US$ Bn) Analysis and Forecast, By End-User, 2025 - 2032
  1. Cattle Farms
  2. Veterinary Clinics
  3. Government Agencies
7. Market Attractiveness Analysis
South Asia & Oceania Bovine Vaccines Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Vaccine Type
  3. By Disease Type
  4. By End-User
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. India
  2. Southeast Asia
  3. ANZ
  4. Rest of South Asia & Oceania
4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Vaccine Type, 2025 - 2032
  1. Live Attenuated
  2. Inactivated
  3. Toxoid
  4. Subunit
  5. DNA vaccines
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 - 2032
  1. FMD
  2. Brucellosis
  3. Bovine respiratory disease
  4. Others
6. Market Size (US$ Bn) Analysis and Forecast, By End-User, 2025 - 2032
  1. Cattle Farms
  2. Veterinary Clinics
  3. Government Agencies
7. Market Attractiveness Analysis
Latin America Bovine Vaccines Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Vaccine Type
  3. By Disease Type
  4. By End-User
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. Brazil
  2. Mexico
  3. Rest of Latin America
4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Vaccine Type, 2025 - 2032
  1. Live Attenuated
  2. Inactivated
  3. Toxoid
  4. Subunit
  5. DNA vaccines
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 - 2032
  1. FMD
  2. Brucellosis
  3. Bovine respiratory disease
  4. Others
6. Market Size (US$ Bn) Analysis and Forecast, By End-User, 2025 - 2032
  1. Cattle Farms
  2. Veterinary Clinics
  3. Government Agencies
7. Market Attractiveness Analysis
Middle East & Africa Bovine Vaccines Market Outlook
1. Key Highlights
2. Historical Market Size (US$ Bn) Analysis, By Market, 2019 - 2024
  1. By Country
  2. By Vaccine Type
  3. By Disease Type
  4. By End-User
  5. By End User
3. Market Size (US$ Bn) Analysis and Forecast, By Country, 2025 - 2032
  1. GCC Countries
  2. Egypt
  3. South Africa
  4. Northern Africa
  5. Rest of Middle East & Africa
4. Market Size (US$ Bn) and Volume (Units) Analysis and Forecast, By Vaccine Type, 2025 - 2032
  1. Live Attenuated
  2. Inactivated
  3. Toxoid
  4. Subunit
  5. DNA vaccines
5. Market Size (US$ Bn) Analysis and Forecast, By Disease Type, 2025 - 2032
  1. FMD
  2. Brucellosis
  3. Bovine respiratory disease
  4. Others
6. Market Size (US$ Bn) Analysis and Forecast, By End-User, 2025 - 2032
  1. Cattle Farms
  2. Veterinary Clinics
  3. Government Agencies
7. Market Attractiveness Analysis
Competition Landscape
1. Market Share Analysis, 2024
2. Market Structure
  1. Competition Intensity Mapping By Market
  2. Competition Dashboard
3. Company Profiles (Details - Overview, Financials, Strategy, Recent Developments)
  1. Zoetis Inc.
    1. Overview
    2. Segments and Components
    3. Key Financials
    4. Market Developments
    5. Market Strategy
  2. Merck Animal Health (MSD)
  3. Boehringer Ingelheim Animal Health
  4. Ceva Santé Animale
  5. Elanco Animal Health
  6. Indian Immunologicals Ltd.
  7. Hester Biosciences Ltd.
  8. Bayer Animal Health
  9. Kyoto Biken Laboratories, Inc.
  10. Virbac
  11. Phibro Animal Health Corporation
  12. Biogenesis Bagó
  13. Brilliant Bio Pharma Pvt. Ltd.
  14. Hipra
  15. Avimex Animal Health
  16. China Animal Husbandry Industry Co., Ltd. (CAHIC)
Appendix
1. Research Methodology
2. Research Assumptions
3. Acronyms and Abbreviations

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Bn/Mn, Volume: As Applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Latin America Middle East and Africa
Segmental Coverage	Vaccine Type Disease Type End-user Region
Competitive Analysis	Zoetis Inc. Merck Animal Health (MSD) Boehringer Ingelheim Animal Health Ceva Santé Animale Elanco Animal Health Indian Immunologicals Ltd. Hester Biosciences Ltd. Bayer Animal Health Kyoto Biken Laboratories, Inc. Virbac Phibro Animal Health Corporation Biogenesis Bagó Brilliant Bio Pharma Pvt. Ltd. Hipra Avimex Animal Health China Animal Husbandry Industry Co., Ltd. (CAHIC)
Report Highlights	Market Forecast and Trends Competitive Intelligence and Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities and Revenue Pockets Market Analysis Tools
Customization and Pricing	Available upon request

Report Attribute	Details
Historical Data/Actuals	2019 - 2024
Forecast Period	2025 - 2032
Market Analysis	Value: US$ Bn/Mn, Volume: As Applicable
Geographical Coverage	North America Europe East Asia South Asia and Oceania Latin America Middle East and Africa
Segmental Coverage	Vaccine Type Disease Type End-user Region
Competitive Analysis	Zoetis Inc. Merck Animal Health (MSD) Boehringer Ingelheim Animal Health Ceva Santé Animale Elanco Animal Health Indian Immunologicals Ltd. Hester Biosciences Ltd. Bayer Animal Health Kyoto Biken Laboratories, Inc. Virbac Phibro Animal Health Corporation Biogenesis Bagó Brilliant Bio Pharma Pvt. Ltd. Hipra Avimex Animal Health China Animal Husbandry Industry Co., Ltd. (CAHIC)
Report Highlights	Market Forecast and Trends Competitive Intelligence and Share Analysis Growth Factors and Challenges Strategic Growth Initiatives Pricing Analysis Future Opportunities and Revenue Pockets Market Analysis Tools
Customization and Pricing	Available upon request

Bovine Vaccines Market Size, Share, Trends, Growth, and Forecasts for 2025 - 2032

Bovine Vaccines Market By Vaccine Type (Live Attenuated, Inactivated, Toxoid), by Disease Type (FMD, Brucellosis, Bovine Respiratory Disease), End-user (Cattle Farms, Veterinary Clinics, and Government Agencies), and Regional Analysis for 2025 - 2032